Investigator Sponsored Studies, grants and sponsorships
Vertex Pharmaceuticals funds independent research and education to advance science and care in cystic fibrosis, pain, IgA nephropathy, blood disorders, and other rare diseases.
Funder: Vertex Pharmaceuticals
Due Dates: Rolling (most programs) | Closed (VIA, RIA, Circle of Care—next cycle opens in 2026)
Funding Amounts: No formal cap for most grants; up to $750,000 over 3 years (RIA, VIA); $125,000 over 2 years (Mentored RIA); multi-year requests accepted.
Summary: Supports independent research, education, and sponsorships advancing care and knowledge in cystic fibrosis, pain, IgA nephropathy, beta thalassemia, sickle cell disease, and other rare diseases.
Key Information: Most programs accept applications year-round; some competitive awards have annual cycles.
Description
Vertex Pharmaceuticals offers a global portfolio of external funding opportunities—including investigator-sponsored studies (ISS), medical education grants, patient advocacy, and organizational sponsorships—focused on advancing scientific research, education, and care for people living with cystic fibrosis, pain, IgA nephropathy, beta thalassemia, sickle cell disease, and other serious or rare diseases. Funding is available for a wide range of activities, including independent clinical and nonclinical research, educational initiatives for healthcare providers and patients, and community-based programs.
Vertex’s ISS program supports independent research projects that align with the company’s areas of interest and is open to institutions, academic centers, and qualified organizations globally. The company also offers specific competitive awards (e.g., Vertex Innovation Awards, Research Innovation Awards, Circle of Care) with defined cycles and funding limits for cystic fibrosis research and patient support.
